Table 1 Participant characteristics
From: A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome
| Â | Cohort 1 | Cohort 2 | Both Cohorts | |||
|---|---|---|---|---|---|---|
Ketamine-Placebo (n = 6) | Placebo-Ketamine (n = 5) | Ketamine-Placebo (n = 6) | Placebo-Ketamine (n = 6) | Ketamine-Placebo (n = 12) | Placebo-Ketamine (n = 11) | |
Demographics [Mean (SD)] | ||||||
 Age in years | 9.3 (2.3) | 7.8 (1.9) | 7.5 (2.1) | 7.7 (2) | 8.4 (2.3) | 7.7 (1.8) |
 Height in cm | 130.7 (13.8) | 120.3 (6.1) | 116.6 (8.4) | 118.2 (10.9) | 124.3 (13.3) | 119.1 (8.7) |
 Weight in kg | 25.1 (7.7) | 23.6 (7.7) | 20.7 (3.8) | 22.4 (5.6) | 22.9 (6.2) | 22.9 (6.3) |
 BMI in kg/m2 | 14.3 (1.4) | 16.1 (4.3) | 14.8 (1.8) | 15.9 (1.9) | 14.5 (1.5) | 16 (3.1) |
Race [# (%)] | ||||||
 White | 5 (83) | 4 (80) | 5 (83) | 6 (100) | 10 (83) | 10 (91) |
 Black | 0 (0) | 1 (20) | 0 (0) | 0 (0) | 0 (0) | 1 (9) |
 Asian | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 1 (8) | 0 (0) |
 Asian and white | 1 (17) | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) |
 Hispanic | 0 (0) | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 1 (9) |
 Not Hispanic | 6 (100) | 5 (100) | 6 (100) | 5 (83) | 12 (100) | 10 (91) |
Baseline Severity [Mean (SD)] | ||||||
 CGI-S | 4.8 (0.8) | 4.4 (0.5) | 4.7 (1) | 4.7 (0.8) | 4.8 (0.9) | 4.5 (0.7) |
 MBA | 47.5 (15.4) | 44.4 (6.6) | 48.7 (10.8) | 45.3 (15.3) | 48.1 (12.7) | 44.9 (11.6) |
 ClinDom | 35.2 (5.1) | 34.4 (4.4) | 32.8 (3.9) | 31.5 (5.2) | 34 (4.5) | 32.8 (4.9) |
 RSBQ | 37.8 (9.6) | 39.8 (6.5) | 44.3 (5.2) | 47.7 (17.8) | 41.1 (8.1) | 44.1 (13.9) |
 CSHQ | 81.5 (18.7) | 91.2 (24.4) | 107.5 (18) | 108.3 (23.6) | 94.5 (22.1) | 100.5 (24.5) |
 ParDom | 36.5 (6.6) | 31.6 (6.4) | 35.2 (10.1) | 40 (7.9) | 35.8 (8.2) | 36.2 (8.2) |
 RTT CIA | 19.5 (3.6) | 40.4 (12.3) | 40.3 (12.2) | 39.5 (20.3) | 29.9 (13.9) | 39.9 (16.3) |